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A B S T R A C T
Introduction: Experimental studies suggest that low-frequency (LF) (63 Hz) deep brain stimulation (DBS) of the
substantia nigra pars reticulata (SNr) could be useful to regulate gait disorders refractory to medical treatment in
Parkinson's disease (PD). The SNr neurons could act as high-frequency (HF) pacemakers within locomotor
control systems. Currently, no specific therapies can treat gait disorders in PD with insufficient response to
dopaminergic treatment.
Objective: To investigate whether LF-SNr-DBS combined with standard HF stimulation of the subthalamic nu-
cleus (STN) is clinically relevant in improving gait disorders that no longer respond to levodopa in PD patients,
compared with HF-STN or LF-SNr stimulation alone.
Methods: Patients received LF-SNr or HF-STN stimulation alone or combined (COMB) stimulation of both nuclei
(crossover design). The nucleus to be stimulated was randomly assigned and clinical evaluations performed by a
blinded examiner after three months follow-up for each. Clinical assessment included the Freezing of Gait
questionnaire, Tinetti Balance and Walking Assessing tool, and Unified Parkinson's Disease Rating.
Results: We included six patients (mean age 59.1 years, disease duration 16.1 years). All patients suffered motor
fluctuations and dyskinesias. The best results were obtained with COMB in four patients (who preferred and
remained with COMB over 3 years of follow-up) and with HF-STN in two patients. SNr stimulation alone did not
produce better results than COMB or STN in any patient.
Conclusion: COMB and HF-STN stimulation improved PD-associated gait disorders in this preliminary case
series, sustained over time. Further multicenter investigations are required to better explore this therapeutic
option.
1. Introduction
One of the most challenging and unresolved problems in Parkinson's
disease (PD) is the treatment of gait disorders unresponsive to dopa-
minergic medication. Patients suffering from gait disorders are not
considered good candidates for subthalamic nucleus deep brain sti-
mulation (STN-DBS) [1]. Currently, there are no specific therapies to
treat gait disorders in PD with an insufficient response to dopaminergic
treatment. Furthermore, axial symptoms develop during disease pro-
gression even in operated patients. Axial symptoms are often one of the
main causes of disability [2]. Nonetheless, there is evidence suggesting
that low-frequency (LF) stimulation of the ventral area of the STN can
improve gait symptoms [3]. The substantia nigra pars reticulata (SNr) is
one of the most important output centers of the basal ganglia and is
integrated within the locomotor control systems. Neurons within the
SNr may act as high-frequency (HF) pacemakers, disrupting normal
behavior downstream in the circuit [4]. Dual HF-STN and LF-SNr sti-
mulation may have beneficial effects in the treatment of gait disorders
unresponsive to dopaminergic therapy [5].
The aim of our study is to evaluate whether LF-SNr-DBS (63 Hz)
combined with dorsolateral HF-STN-DBS produces clinically relevant
improvements in gait disorders compared with conventional HF-STN-
or LF-SNr-DBS alone in PD patients.
https://doi.org/10.1016/j.parkreldis.2018.09.008
Received 31 May 2018; Received in revised form 4 September 2018; Accepted 4 September 2018
∗ Corresponding author.
E-mail addresses: fvallde@clinic.cat, fvallde@clinic.ub.es (F. Valldeoriola).
Parkinsonism and Related Disorders 60 (2019) 153–157




This is a prospective, randomized, crossover pilot study with
blinded clinical evaluations. The study and informed consent were
approved by the Hospital Clinic of Barcelona Ethics Committee (HCB/
2017/0716). The study conforms to the Declaration of Helsinki. All
included patients signed an informed consent.
2.1. Clinical assessment
We included six patients diagnosed with PD who were unsuitable
candidates for STN-DBS due to the presence of gait disorders with an
insufficient response to best dopaminergic treatment. Demographic
data and medication was noted, along with video recording and ad-
ministration of several clinical scales, in best medication “on” and
overnight “off” conditions. Clinical assessments included Freezing of
Gait (FoG) Questionnaire (self-administered) [6], Unified Parkinson's
Disease Rating Scale (UPDRS) in off and on condition, Timed Up-and-
Go (TUG) test, and Tinetti Balance and Walking Assessing tool [7]
(Spanish version). Adverse effects (AEs), and stimulation parameters
were recorded at each follow-up visit.
The baseline visit (Supplementary Fig. 1) was performed 3 months
before the surgical procedure for candidate screening, administration of
scales and informed consent. Stimulation was initiated one week after
surgery. Optimization of medication and electrical parameters for each
target was done by a movement disorders specialist (FV) during a 3-
month window following surgery.
Patients were randomized to receive either HF-STN-DBS or LF-SNr-
DBS and were evaluated after a 3-month follow-up period. After 3
months, all patients crossed over to COMB stimulation, using optimal
settings obtained in the previous phases, and also evaluated after 3
months. All assessment scales were evaluated by a rater (EM) blinded to
the stimulation target, parameters, and medication.
2.2. Statistical analysis
Given the small number of patients in this study, only descriptive
statistics were used.
2.3. Surgical procedure
Bilateral STN-DBS was carried out through stereotaxy and conscious
sedation. A stereotactic planning software (iPlan from BrainLab AG,
Munich, Germany) was used to determine STN coordinates, based on
direct targeting in 3 T MRI. Intraoperative microrecordings and stimu-
lation (Neuroset, Neurostar GmbH, Tübingen Germany) were used to
confirm an adequate location before implanting the electrode
(ModelDB-2201-45, Boston Scientific, Valencia, CA). The interface be-
tween the STN and SNr was determined based on microelectrode re-
cording. The macroelectrode was advanced 3mm below the identified
ventral border of the STN. Intraoperative stimulation was also carried
out at the most ventral border of the dorsolateral STN. This procedure
enabled us to stimulate the SNr as well as the dorsolateral STN. Finally,
a neurostimulator (Vercise DB-1110-C, Boston Scientific, Valencia, CA)
was implanted. The final lead location was determined by cranial MRI
24 h after surgery.
2.4. Stimulation parameters
The pulse width was set to 60 μs in all patients and stimulation
amplitude was adjusted to maximize the patient's clinical benefits via
monopolar review. The objective of the dual stimulation was to use a
frequency of 126 Hz (HF) for STN-DBS and 63 Hz (LF) for SNr-DBS in
both hemispheres, for a total of four different stimulation areas. The
neurostimulator used meant that if more than two areas were ON, all
areas should have the same rate. To resolve this, we decided to double
the rate by stimulating one area at 63 Hz targeting both the STN and
SNr, and then creating another area at 63 Hz targeting the STN only, so
the frequency of pulses would be double at the STN (i.e. 126 Hz). We
calculated the desired amplitude in the area where the STN and SNr
were stimulated simultaneously, taking advantage of multiple, in-
dependent current-controlled technology, which allows different per-
centages of current to be delivered independently. Due to a safety
feature of the device preventing the temporal overlap of stimulation
pulses to different areas, the exact temporal fidelity between any two
pulses in the HF stimulation cannot be guaranteed to be fixed.
Nonetheless, this safety feature does not affect the frequency of sti-
mulation delivered.
3. Results
3.1. Demographic and clinical data
We included six patients (five male), with a mean age of 59.1 (range
43–70) years, mean disease duration of 16.1 (10–20) years, and mean
“on” freezing duration of 7.3 (3–15) years. Two of the patients had
early onset PD (starting at ages 43 and 37), with both patients ex-
hibiting mutation in the gene encoding the ‘Parkin’ protein. The levo-
dopa equivalent dose (LEDD) was 1250 ± 427 (550–1850) mg/day.
All patients suffered motor fluctuations and troublesome peak dose
dyskinesias. Details of the contacts and stereotactic coordinates for each
patient can be found in Supplementary Table 1.
3.2. Motor assessment
Self-administered FoG questionnaire. Evaluation of gait in the
worst condition indicated that at baseline, two patients were unable to
walk and four required a cane; after treatment, gait improved (i.e. al-
most normal gait or no help needed) in four patients after COMB sti-
mulation, two patients after HF-STN-DBS, and one patient after LF-SNr-
DBS.
All patients presented the maximal score for FoG at baseline
(Fig. 1A), indicating that FoG is always present when walking. At final
follow-up, the prevalence of FoG in COMB patients was “never” (one
patient), “very rarely or once per month” (one patient), “rarely or once
per week” (one patient), or “continuous” (three patients). Un-
expectedly, HF-STN-DBS patients presented with a FoG prevalence of
“never” (one patient), “very rarely” (one patient), or “continuous” (four
patients). Duration of freezing (Fig. 1B) was reduced in five patients
after COMB stimulation and two patients after HF-STN-DBS. Start
hesitation (Fig. 1C) did not occur in two patients with COMB stimula-
tion and one patient with HF-STN-DBS, and improved in four patients
after COMB stimulation and four patients after HF-STN-DBS. Duration
of freezing while turning (Fig. 1D) was clearly reduced in five patients
with COMB stimulation, three with HF-STN-DBS, and five with LF-SNr-
DBS. Freezing when turning (Fig. 1D) disappeared in one patient after
COMB stimulation, and in one patient after HF-STN-DBS.
An improvement in activities of the daily living was noted after all
interventions (Table 1). All six patients had a severe gait disorder at
baseline (as per the inclusion criteria); after intervention, improvement
(no, or slight problems) was observed in five patients after COMB, two
after HF-STN-DBS, and three patients after LF-SNr-DBS.
Tinetti Balance and Walking Assessing tool. All three stimulation
paradigms resulted in benefits in equilibrium, gait, and total scores
when compared to baseline, with COMB stimulation toward slightly
increased benefit over either STN or SNr stimulation alone
(Supplementary Figs. 2a and b).
UPDRS part II and III. Scores of the UPDRS II and III, axial items
(28, 29, 30, 31) of the UPDRS, and item 29 (gait), “on” and “off”
medication, at baseline and at the end of each follow-up assessment in
the different targets are shown in Table 1.
Medication. LEDD reduction was 63% for HF-STN-DBS alone, 43%
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for LF-SNr-DBS alone, and 53% for COMB stimulation.
3.3. Stimulation parameters
For HF-STN-DBS alone, the mean amplitude was 2.9 ± 0.5 (range
2–3.5) mA in the right hemisphere and 2.9 ± 0.6 (2–3.6) mA in the
left. For LF-SNr-DBS alone, amplitude was 4 ± 1 (3–5.5) mA in the
right hemisphere and 4.8 ± 0.5 (4–5.2) mA in the left. For HF-STN-
DBS, monopolar setup was used in all patients in both sides, using
dorsal contacts. For LF-SNr-DBS, we programmed a monopolar setup in
two patients and bipolar configuration in the other four patients, using
the most ventral contacts in both sides.
Four out of the six patients preferred to maintain dual stimulation
after the study (COMB). Final parameters for HF-STN-DBS were 3 ± 1
(2–4) mA on the right side and 2.6 ± 0.9 (2–4) mA on the left. For LF-
SNr-DBS, right parameters were 3.6 ± 1.4 (2.5–5.6) mA and left
2.3 ± 2 (0.8–5) mA. The two remaining patients decided to receive
HF-STN-DBS alone.
3.4. Adverse effects
No intraoperative AEs were observed. Postoperative AEs included
confused state (one patient), which improved after two weeks and re-
solved in 1 month. Transitory AEs included blurred vision (two LF-SNr-
DBS patients), and muscular twitching (two HF-STN-DBS patients),
both corrected after reducing the stimulation amplitude. One patient
developed depressive symptoms after STN stimulation, which did not
improve after switching OFF the stimulator for one week and which
were attributed to dopamine agonist withdrawal.
4. Discussion
To our knowledge, this pilot study is the first to study the effects of
simultaneous DBS in both the STN and SNr at different frequencies in
PD (COMB stimulation). New stimulation systems allow independent
stimulation with multiple frequencies, enabling easy evaluation of the
impact of stimulating different targets at different frequencies. Our
study was designed to specifically analyze the possible efficacy of such
approach in improving levodopa-unresponsive FoG. Our results show
that COMB produced a sustained improvement in PD-associated gait
Fig. 1. Sub-scores obtained in the self-administered version of the Freezing of Gait Questionnaire at baseline and after three months of stimulation under the different
conditions of the study (HF-STN, LF-SNr and COMB). The X axis represents four of the specific items of the scale; the Y axis refers to the number of patients scoring the
specific item.
A) Freezing of gait: Do you feel that your feet get glued to the floor while walking, making a turn or when trying to initiate walking (freezing)?
B) Duration of freezing: How long is your longest freezing episode?
C) Start hesitation: How long is your typical start hesitation episode (freezing when initiating the first step)?
D) Freezing while turning: How long is your typical turning hesitation (freezing when turning)?
COMB, combined, simultaneous stimulation of the STN (HF) and the SNr (LF); HF, high frequency; LF, low frequency; SNr, substantia nigra reticulata; STN,
subthalamic nucleus.
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disorders.
The SNr is a major output nucleus of the basal ganglia, sending
projections to the brainstem and thalamus. SNr projections to the
pontine tegmental region are involved in posture control [8]. The first
data to suggest that LF stimulation of the STN reduces the number of
freezing episodes in PD patients compared to HF (130 Hz) stimulation
came from Moreau et al. [3], who concluded that the frequency of STN-
DBS could be changed to 60 Hz at high voltage to improve axial
symptoms in PD patients that develop severe gait disorders. This study
also found that FoG worsens when the voltage was increased at LF
stimulation. The change in the clinical response following variations in
the stimulation frequency is controversial.
One study has shown improvement or non-worsening of FoG using
frequencies lower than 100 Hz [9]; others have demonstrated transient
[10] absence of effect of LF stimulation [11]. We tested LF stimulation
of the STN using the most ventral contacts in several patients who
developed gait problems during disease progression after chronic DBS,
and obtained clear improvements in the number of freezing episodes
and step length in some of them.
A crossover, double-blind, randomized controlled trial using STN-
vs. dual stimulation at HF, using interleaved pulses in 12 PD patients,
showed that HF, interleaved, combined stimulation improved the
Freezing of Gait Assessment Course without changes in postural control
[5]. In a recent review [12], it was found that overall LF stimulation
seemed to be consistently effective in patients with FoG previously
treated with standard HF stimulation.
Four out of six patients achieved better global results with COMB
stimulation than HF-STN- or LF-SNr-DBS alone. These patients pre-
ferred and remained with COMB over three years follow-up. Our results
seem to be more promising than those obtained with combined sti-
mulation at 130 Hz [5]. LF-SNr-DBS alone resulted in a relative im-
provement in FoG, but the global antiparkinsonian effect was lower
than that achieved with HF-STN-DBS. Blurred (double) vision was a
limitation to increasing intensity in two patients stimulated in the SNr.
Behavioral changes have been reported when stimulating ventral and
medial areas of the STN. We did not observe cognitive changes after
stimulation in any target. One patient developed depressive symptoms
after STN stimulation that were attributed to dopamine agonist with-
drawal. Similarly, in a study showing the effects of STN and SNr sti-
mulation at high frequencies no serious behavioral or psychiatric ad-
verse effects were found [5].
Some patients also obtained remarkable benefit in the amelioration
of “on” freezing with isolated HF-STN stimulation – which may be one
of the more remarkable finding of our study. The beneficial effects on
gait observed with COMB stimulation and isolated STN stimulation
were maintained for three years after the intervention, ruling out the
possibility of any placebo effect. Although improvement of FoG is
challenging in patients stimulated in the STN as the disease progresses,
this finding could be considered in the future for patients with medi-
cally-untreatable FoG with otherwise good response to levodopa in
other parkinsonian signs. The low number of cases included in this
preliminary pilot study makes it absolutely necessary to develop further
multicentric investigations to obtain the sufficient number of patients
and obtain more consistent conclusions regarding this challenging
topic.
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